← All drugs Report issue

tj033721

mAbexperimentalBi-specific

Clinical trial activity

1 trials · 1 clinical orgs · 0 marketing orgs

Phase 1

1

Phase 2

0

Phase 3

0

Phase 4

0

Earliest trial started Jun 29, 2021 (NCT04900818)

Timeline

2020s

Jan 1, 2021
Earliest Phase 1 Sponsor(trial)

Indications

Studied for

Mechanism of action

Tumor necrosis factor receptor superfamily member 9ANTAGONIST
TNFRSF9 antagonist
- Tumor necrosis factor receptor superfamily member 9 (TNFRSF9) ↗
Claudin-18ANTAGONIST
CLDN18 antagonist
- Claudin-18 (CLDN18) ↗

Chemistry & pharmacology

Chirality: Single Stereoisomer
Inorganic: No
Polymer: No
Multi-specific: Yes (Bi-specific)

Oral

No

Parenteral

No

Topical

No

Sources

ChEMBLCHEMBL5314837 ↗

Clinical trials

NCT ID	Phase	Start date	Sponsor(s)
NCT04900818	Phase 1	Jun 29, 2021	I-Mab Biopharma

Showing 1 of 1 trials

Page 1 / 1

Organizations

Research & Development (1)

Organization	Org type	Trials	As lead sponsor	Phases	Earliest year
I-Mab Biopharma	For profit	1	1	1	2021

1 organizations

Page 1 / 1